STI-6643 for Refractory Tumors

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Refractory Tumors+2 MoreSTI-6643 - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug for people with cancer that has come back or didn't respond to other treatments. It's the first time this drug is being given to humans.

Eligible Conditions
  • Refractory Tumors
  • Solid Tumors
  • Relapsed Solid Tumor

Treatment Effectiveness

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: Baseline through study completion at up to approximately 31 months

Month 31
Safety of STI-6643
Day 15
Anti-drug antibodies directed to STI-6643
Day 22
PK parameters
STI-6643 receptor occupancy
Month 31
Duration of response
Overall response rate

Trial Safety

Trial Design

1 Treatment Group

STI-6643
1 of 1

Experimental Treatment

100 Total Participants · 1 Treatment Group

Primary Treatment: STI-6643 · No Placebo Group · Phase 1

STI-6643
Biological
Experimental Group · 1 Intervention: STI-6643 · Intervention Types: Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline through study completion at up to approximately 31 months

Who is running the clinical trial?

Sorrento Therapeutics, Inc.Lead Sponsor
47 Previous Clinical Trials
2,375 Total Patients Enrolled
1 Trials studying Refractory Tumors
Mike Royal, MDStudy DirectorSorrento Therapeutics, Inc.
27 Previous Clinical Trials
1,650 Total Patients Enrolled
1 Trials studying Refractory Tumors

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a hemoglobin level of 12 grams per deciliter or more.
You have a solid tumor that has relapsed, is refractory to, or intolerant of standard of care therapy.
You have no available approved therapy that may provide clinical benefit.
You have an absolute neutrophil count (ANC) of at least 1500/mm3.